secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001104659-26-022539
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio reports 2025 net loss of $45.5M; cash runway through Q1 2027; advances FTD clinical program
--------------------------------------------------------------------------------

- Cash and cash equivalents $46.3M at Dec 31, 2025; funding expected through Q1 2027.
- Net loss of $45.5M ($14.35/diluted share) for 2025, improved from $64.8M ($21.04/sh) in 2024.
- R&D expenses $23.3M in 2025, down from $40.2M in 2024; G&A $19.9M vs $25.0M.
- Enrolled first 3 FTD-GRN patients in Cohort 3; dosed first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4.
- Expects interim safety/biomarker data and regulatory feedback on FTD-GRN registrational trial in 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000110465926022539/0001104659-26-022539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000110465926022539/pasg-20260303x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-022539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer